NewCardio, Inc. operates as a life sciences company specializing in the early detection and assessment of cardiotoxicity in preclinical drug development. The company develops and commercializes proprietary in vitro assay platforms and software tools designed to identify potential cardiac liabilities of small-molecule and biologic drug candidates. By integrating stem cell–derived cardiomyocytes with high-throughput electrophysiological measurements, NewCardio’s technology enables pharmaceutical and biotechnology firms to assess drug safety profiles more efficiently and reduce the risk of late-stage clinical failures.
At the core of NewCardio’s offerings is its CardioXpress biochip system and accompanying data analytics suite. The biochip leverages microelectrode array (MEA) technology to record electrical activity from cultured heart cells, while the analytics suite applies machine learning algorithms to detect subtle changes in beat rate, action potential duration, and arrhythmic events. In addition to preclinical screening services, the company provides custom assay development, training workshops, and ongoing technical support to contract research organizations and academic laboratories.
Founded in 2013 and headquartered in Calgary, Alberta, NewCardio has expanded its footprint to include offices and laboratory facilities in the United States and Europe. Over the last decade, the company has formed strategic collaborations with leading university research centers and global pharmaceutical partners to validate its platform against industry-standard safety assays. These collaborations have enabled NewCardio to fine-tune its methodology and accelerate adoption of its technology across North America, Asia, and the European Union.
NewCardio’s leadership team combines expertise in electrophysiology, regenerative medicine, and regulatory science. The company is led by CEO Scott McCulloch, whose background in biotech entrepreneurship has guided NewCardio through multiple financing rounds and product launches. Supporting him are a small executive team of seasoned professionals, including a chief scientific officer with extensive experience in cardiac toxicology and a vice president of business development responsible for expanding global partnerships and sales channels.
AI Generated. May Contain Errors.
